Study guide

5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials

Certified Medical Publication Professional CMPP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Preparation Strategy

1.1 ISMPP CMPP Certification Overview, Eligibility & Exam Format 1.2 Recertification, Continuing Education (CE) Credits & ISMPP U 1.3 Core Reference Hierarchy, Primary Documents & Test-Taking Strategy

2 Chapter 2: Publication Planning: Strategy, Environment & Scientific Platform

2.1 Medical Publication Lifecycle & Strategic Planning Frameworks 2.2 Therapeutic Landscape Analysis, Unmet Needs & Gap Analysis 2.3 Scientific Communication Platforms and Evidence-Based Language

3 Chapter 3: Publication Planning: Governance, Steering Committees & Venue Selection

3.1 Publication Steering Committees: Charters, Roles & Scientific Governance 3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators 3.3 Venue Selection, Open Access, and Congress Strategy

4 Chapter 4: Publication Planning: Operations, Contracting, Global Alignment & Compliance

4.1 Publication Agreements, Review Rights, Compensation & Disclosure 4.2 Milestones, Gantt Charts, Budgeting & Vendor/Agency Management 4.3 Global vs. Regional/Local Publication Alignment & Localization 4.4 Publication SOPs, Documentation, Quality Control & Audit Readiness

5 Chapter 5: Reporting Guidelines: Foundational Standards & Trial Reporting

5.1 EQUATOR and Design-Specific Reporting Guidelines 5.2 CONSORT 2025 & Flow Diagrams for Randomized Trials 5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials

6 Chapter 6: Reporting Guidelines: Observational, Reviews & Preclinical

6.1 PRISMA 2020 for Systematic Reviews & Meta-Analyses 6.2 STROBE & RECORD for Observational and Routinely Collected Data 6.3 ARRIVE 2.0 for In Vivo Animal Research

7 Chapter 7: Specialized Reporting, Plain Language Summaries & Congress Submissions

7.1 STARD 2015, CARE, and Specialized Reporting Guidelines 7.2 Plain-Language Summaries and Patient Partnership 7.3 GPCAP 2026: Congress Abstracts, Presentations & Encores 7.4 Digital Publication Features, Accessibility, and Social Dissemination

8 Chapter 8: Manuscript Lifecycle: Drafting, Peer Review, Open Access & Metrics

8.1 Manuscript Development, Author Review, and Sponsor Boundaries 8.2 Peer Review, Rebuttals, Revisions, and Appeals 8.3 Preprints, Creative Commons & Current Open-Access Requirements 8.4 Post-Publication Metrics and Correcting the Record

9 Chapter 9: Ethical Principles: GPP 2022, Authorship Criteria & Contributorship

9.1 Good Publication Practice 2022: Principles, Scope & Application 9.2 ICMJE Authorship Criteria and Qualification Scenarios 9.3 Nonauthor Contributors, Acknowledgments, and CRediT

10 Chapter 10: Ethics & Transparency: Ghostwriting, Writing Assistance, COI & Disclosure

10.1 Ghostwriting, Guest Authorship, and Authorship Disputes 10.2 Professional Medical Writing: Roles, Authorship, Disclosure & Funding 10.3 Disclosure of Interests and Publication Transparency 10.4 Open Payments, EFPIA Codes & Publication-Related Transfers of Value

11 Chapter 11: Compliance & Legal: Clinical Trial Registration, Data Sharing, Regulatory & Ethics

11.1 Trial Registration and Results Disclosure: US, EU, and ICMJE 11.2 Clinical-Trial Data-Sharing Statements and FAIR Principles 11.3 FDA SIUU Guidance & Promotional/Scientific Communication Boundaries 11.4 2024 Declaration of Helsinki, Ethics Review, Privacy & Copyright

5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials

Key Takeaways Explain This Topic AI

SPIRIT 2025 is the current core protocol-reporting standard and contains a 34-item checklist plus a figure.

A protocol is prospective: it should define objectives, outcomes, interventions, allocation, analyses, oversight, ethics, data handling, and dissemination before results are known.

Protocol amendments require version control, dates, rationale, approval, communication, and consistent updates to registries and related documents.

CONSORT 2025 reports completed randomized trials, while SPIRIT 2025 addresses what an interventional-trial protocol should contain.

SPIRIT improves protocol completeness but does not replace ethics approval, registration, regulatory authorization, local law, or trial-specific operating documents.

Last updated: October 2026

SPIRIT 2025: Standard Protocol Items for Interventional Trials

Note

SPIRIT 2025 is the current core guideline for the content of interventional-trial protocols. It supersedes the 2013 statement and provides a 34-item checklist plus a figure. It is paired conceptually with CONSORT 2025: SPIRIT addresses the plan; CONSORT addresses the report of a completed randomized trial.

Why Protocol Reporting Matters

A protocol is the prospective record of why a trial is being done and how it will be designed, conducted, analyzed, overseen, and disseminated. Complete reporting helps investigators implement the same plan across sites, enables ethics committees and regulators to review the study, supports monitoring, and lets readers distinguish prespecified decisions from later changes.

SPIRIT does not guarantee good design. It tells authors what information a protocol should report. Ethics approval, regulatory authorization, prospective registration, contracts, manuals, the statistical analysis plan (SAP), data-management plan, and standard operating procedures remain separate controls.

Administrative Information

The protocol should be identifiable and traceable. Include a descriptive title, trial registration information, protocol version and date, funding, and the names and roles of sponsors and other responsible parties. Describe the sponsor's role in design, data collection, analysis, interpretation, report writing, and the decision to submit results.

Roles and responsibilities matter because “sponsor” may refer to legal responsibility while day-to-day tasks are delegated to a coordinating center, contract research organization, data monitoring committee, or investigators. Delegation does not erase accountability. State who owns or controls the data and who has access.

Background, Rationale, and Objectives

Explain the clinical question and the evidence supporting the trial. Describe the intervention and comparator sufficiently to justify the study. State specific objectives or hypotheses and identify the trial framework, such as superiority, noninferiority, or equivalence.

The rationale should address benefits and risks without promotional framing. If patients, caregivers, or public partners contributed to the research question or protocol, report their involvement as required by the current checklist and applicable policies.

Trial Design

Describe:

  • the type of trial;
  • allocation ratio;
  • framework;
  • number and structure of groups;
  • important design features, such as parallel, crossover, cluster, factorial, or adaptive elements;
  • the study setting and participating-site context;

start and planned end points where relevant.

A visual schedule or SPIRIT figure organizes enrollment, interventions, and assessments across time. It should agree with the narrative and the schedule used operationally.

Participants and Recruitment

State inclusion and exclusion criteria for participants and, where relevant, for centers or individuals delivering an intervention. Describe recruitment strategies and the consent process. Eligibility criteria should be scientifically justified and reviewed for avoidable exclusion or inequity.

For vulnerable populations or those with limited decision-making capacity, describe the protections and applicable consent or assent procedures. If biological specimens or ancillary studies are planned, explain the consent and governance relevant to those uses.

Interventions and Concomitant Care

Describe each intervention with enough detail for consistent delivery. Include criteria for modifying or discontinuing assigned interventions, adherence strategies, and permitted or prohibited concomitant care. Explain relevant post-trial access or care arrangements.

A protocol should not use vague phrases such as “standard care” when standard care varies by site or country. Define the comparator or explain how local practice will be documented.

Outcomes and Assessment Schedule

For each primary and secondary outcome, define:

  • the specific measurement variable;
  • analysis metric;
  • method of aggregation;
  • assessment time point;

who or what performs the measurement when relevant.

Align outcomes across the protocol, registry, SAP, case-report forms, and later publications. If an outcome changes, preserve the audit trail and explain the amendment. Do not overwrite the earlier plan as though it never existed.

The schedule figure should show major enrollment, intervention, and assessment events. Inconsistency between a table, diagram, and narrative is a practical implementation risk and a future publication problem.

Sample Size and Analysis

Explain the sample-size calculation, including the outcome, expected effect or margin, variability or event assumptions, power, significance level, loss-to-follow-up allowance, and any design effect relevant to clusters or repeated measurements.

Prespecify the principal analysis, analysis population, covariate adjustment, handling of missing data, subgroup analyses, and additional methods as appropriate. The protocol can refer to a separate SAP, but the documents must be version-controlled and consistent. Plans for interim analysis and stopping should identify decision rules and who may see comparative results.

Randomization and Masking

For randomized trials, report:

  • how the allocation sequence will be generated;
  • how assignment will be concealed until enrollment;
  • who will generate the sequence, enroll participants, and assign interventions;
  • who will be masked and how;

when and how unmasking is permitted.

These details reduce the chance that implementation choices will be improvised after enrollment begins.

Data Management, Confidentiality, and Oversight

Describe how data will be collected, entered, coded, secured, checked, and retained. Address confidentiality and access. Explain monitoring, auditing, harms collection, and the composition and independence of any data monitoring committee, or explain why one is not needed.

Specify processes for adverse-event reporting and trial stopping. Oversight structures should fit trial risk; the guideline does not require every trial to use the same committee architecture.

Ethics, Consent, and Dissemination

State plans for research-ethics approval and informed consent, including authorized waivers or alternative processes where legally and ethically appropriate. Describe how important protocol amendments will be approved and communicated to investigators, participants, registries, journals, regulators, or other parties as applicable.

Include plans for communicating results to participants and the public, publication policy, authorship or contributor principles, and access to protocol, data, code, and other materials where applicable. A dissemination plan should include unfavorable and inconclusive findings, not only positive results.

Amendment Control

A material amendment should create a traceable record: identified need → scientific/operational review → revised version and date

  • → required ethics/regulatory approval → registry/document updates
  • → communication and implementation

Record what changed, why, when, and who approved it. Synchronize the protocol, SAP, registry, consent materials, manuals, and publication plan. The final publication should disclose important changes from the planned methods or outcomes.

SPIRIT and CONSORT Compared

  • Question SPIRIT 2025 CONSORT 2025
  • Main document Trial protocol Completed randomized-trial report
  • Timing Before and during conduct After outcome data are available
  • Core checklist 34 items 30 items
  • Visual tool Schedule figure Participant-flow diagram
  • Central purpose Prespecify and communicate the plan Transparently report conduct and results

The guidelines are complementary. A well-reported protocol makes later CONSORT reporting easier, but the results report must still explain actual conduct and deviations.

Publication Professional Workflow

Before a protocol manuscript is submitted:

  • download the current SPIRIT 2025 checklist and identify extensions;
  • confirm version number and date;
  • reconcile protocol, registry, SAP, consent materials, and schedule;
  • verify roles, funding, sponsor involvement, and data access;
  • check all outcomes and time points;
  • map checklist items to page numbers;
  • obtain required approvals and author confirmation;

follow the journal's instructions.

Important

The current number to remember is 34 SPIRIT 2025 checklist items , not 33 items from SPIRIT 2013. The deeper principle is prospective transparency: readers should be able to see the planned question, methods, analysis, oversight, ethics, and dissemination before results can influence those choices.